

2026

# Taiwan Liver Cancer Association Annual Meeting

From Multi-omics to Curative Intent in the Era of Systemic Therapy  
May 16-17, 2026 11F, Room 1101, Evergreen International Convention Center

## 2026/05/16 Saturday (12:30 – 17:40)

Time	Topic	Speaker	Moderator
12:30-13:00	Registration		
13:00-13:30	Free paper award presentation		<b>Tsung-Jung Lin</b> TLCA Deputy Secretary General
13:30-13:40	Opening remarks	<b>Yi-Hsiang Huang</b> TLCA President <b>Chun-Yen Lin</b> TLCA Annual Meeting Chair	
<b>Session 1. Precision Medicine Toolbox for HCC</b>			
13:40-14:00	Single-cell atlas of the immune microenvironment in HCC	<b>Shih-Yu Chen</b> Institute of Biomedical Sciences, Academia Sinica	<b>Chun-Jen Liu</b> National Taiwan University Hospital
14:00-14:20	Transcriptomics & spatial biology toward clinically usable biomarkers	<b>Hsuan Liu</b> Chang Gung University	<b>Chia-Yen Dai</b> Kaohsiung Medical University, Chung-Ho Memorial Hospital
14:20-14:40	Microbiome modulation and FMT to enhance immunotherapy efficacy in HCC	<b>Pei-Chang Lee</b> Taipei Veterans General Hospital	<b>Chia-Chi Wang</b> Taipei Tzu Chi Hospital
14:40-15:00	Radiomics for treatment response prediction and decision support: from model validation to workflow	<b>I-Cheng Lee</b> TLCA Secretary General	<b>Pin-Nan Cheng</b> National Cheng Kung University Hospital
15:00-15:20	Coffee Break		
<b>Session 2. Curative Intent After Systemic Therapy</b>			
15:20-15:40	The role of ablation in the era of systemic treatment for advanced HCC	<b>Hung-Wei Wang</b> China Medical University Hospital	<b>Ming-Jong Bair</b> Taitung MacKay Memorial Hospital
15:40-16:05	Optimal Neoadjuvant Immunotherapy Trial Design in HCC: Less Is More	<b>Ying-Chun Shen</b> NTU Cancer Center	<b>Ann-Lii Cheng</b> Honorary Hospital Director NTU Cancer Center
16:05-16:25	Immunotherapy as a Bridging or Downstaging Strategy Before Liver Transplantation	<b>Jin-Chiao Lee</b> Linkou Chang Gung Memorial Hospital	<b>Gar-Yang Chau</b> Taipei Veterans General Hospital
16:25-16:45	When to transfer patients to liver transplantation after systemic therapy	<b>Ming-Che Lee</b> Shuang Ho Hospital	<b>Jiunn-Chang Lin</b> MacKay Memorial Hospital
16:45-17:05	From Curative Intent to Combination Strategies: The Taiwan Experience in Unresectable HCC Treatment with Selective Internal Radiation Therapy (SIRT)	<b>Chien-An Liu</b> Taipei Veterans General Hospital	<b>Po-Chin Liang</b> National Taiwan University Hospital
<b>Satellite Symposium</b>			
17:05-17:40	Roche symposium		
18:30-21:00	GALA DINNER		

主辦單位:



台灣肝癌醫學會

協辦單位:



林口長庚紀念醫院  
Chang Gung Memorial Hospital, Linkou



長庚大學  
CHANG GUNG UNIVERSITY

報名連結: <https://forms.gle/KQLLKyqxsq7SPDrj8>



# 2026

# Taiwan Liver Cancer Association Annual Meeting

From Multi-omics to Curative Intent in the Era of Systemic Therapy  
May 16-17, 2026 11F, Room 1101, Evergreen International Convention Center

## 2026/05/17 Sunday (08:00 – 15:20)

Time	Topic	Speaker	Moderator
08:00-08:30	Registration		
08:30-08:50	TLCA assembly meeting		
<b>Session 3. KLCA-TLCA Joint Symposium</b>			
09:00-09:20	How to predict treatment response or prognosis in ICI-treated HCC patients	<b>Do Young Kim</b> KLCA Audit Yonsei University, Seoul, Korea	<b>June Sung Lee</b> KLCA President Inje University, Gimhae, Korea
09:20-09:40	Locoregional alternatives for TACE-unsuitable HCC: Taiwan perspective (HAIC/SBRT/Proton/TARE/Histotripsy)	<b>Chien-Hung Chen</b> NTU Cancer Center	<b>Yi-Hsiang Huang</b> TLCA President
09:40-10:00	Y90 for HCC in Korea	<b>Hyo-Cheol Kim</b> Seoul National University, Seoul, Korea	<b>June Sung Lee</b> KLCA President Inje University, Gimhae, Korea
10:00-10:10	Panel discussion		<b>June Sung Lee and Yi-Hsiang Huang</b>
10:10-10:15	Group Photo	<b>TLCA &amp; JLCA &amp; KLCA</b>	
10:15-10:30	Coffee Break		
<b>Session 4. JLCA Keynote Lecture</b>			
10:30-11:00	Systemic therapy for HCC- Current status and future directions	<b>Masatoshi Kudo</b> Kindai University, Osaka, Japan	<b>Chung-Kwe Wang</b> TLCA Honorary President
11:00-11:25	Strategies to overcome immune-excluded microenvironment for HCC	<b>Takahiro Kodama</b> Osaka University, Osaka, Japan	<b>Chun-Yen Lin</b> TLCA Annual Meeting Chairman
11:25-11:50	Strategies to enhance resectability and minimize recurrence risk in HCC	<b>Kiyoshi Hasegawa</b> Tokyo University, Tokyo, Japan	<b>Wei-Chen Lee</b> Linkou Chang Gung Memorial Hospital
<b>Satellite Symposium</b>			
12:00-12:35	AZ symposium		
12:35-13:10	Eisai / MSD symposium		
13:10-13:45	BMS / Ono symposium		
<b>Session 5. Emerging Therapeutic Strategies Shaping the Future of HCC</b>			
14:00-14:20	Therapeutic tools for MASLD that may change HCC risk	<b>Jee-Fu Huang</b> Kaohsiung Medical University, Chung-Ho Memorial Hospital	<b>Yu-Lueng Shih</b> Taichung Armed Forces General Hospital
14:20-14:40	Transforming HCC Management: The Expanding Role of radiotherapy in Clinical Practice	<b>Bing-Shen Huang</b> Linkou Chang Gung Memorial Hospital	<b>Chao-Hung Hung</b> Kaohsiung Chang Gung Memorial Hospital
14:40-14:50	Closing remark	<b>Yi-Hsiang Huang</b> TLCA President	
<b>Session 6. TLCA Research Group (TRG) Progress Report</b>			
14:50-15:20	TRG research updates		<b>Shi-Ming Lin</b> TLCA Honorary President